Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients ( n = 1,090), we observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition responses elicited by a single vaccine dose in individuals with prior SARS-CoV-2 infection ( n = 35) were similar to those seen after two doses of vaccine in individuals without prior infection ( n = 228). Post-vaccine symptoms were more prominent for those with prior infection...